March 06, 2019

Tumor Mutational Burden (TMB) Assay for Response to Immunotherapy

TMB assay utilizing whole exome sequencing (WES) methodology and proprietary variant analysis compendium
Tumor Mutational Burden (TMB) is a putative biomarker of response to checkpoint inhibitor therapy. Q2 Solutions | EA Genomics offers a TMB assay that utilizes a whole exome sequencing (WES) of tumor specimens for reliable quantification of TMB across various tumor indications. 

Learn more about our TMB assay specifications and our comprehensive portfolio of genomic assays for immuno-oncology applications.

Related Services:
Genomic Based Solutions for Your Immuno-oncology Drug Development Needs

Genomics-based biomarker approach

The standardization of Tumor Mutational Burden (TMB) by alignments to reference standards

Joined by Friends of Cancer Research (Friends)

Q2 Solutions Biomarker Services

Providing tools and experience to maximize your biomarker strategy

Panel-based tumor mutational burden (TMB) analysis of matched tumor and plasma specimens using Illumina’s TruSight Oncology 500 next-generation sequencing assay

AACR 2019 Scientific Poster

Anatomic Pathology brochure

Comprehensive in-house end-to-end anatomic pathology and adjunct molecular services

Read More